title: Basal prolactin values correlate with response to reboxetine treatment in major depression, but not with response to citalopram.
abstract: Little is known about variables that might predict outcome in major depression. Recently, basal prolactin values (BPV) have been suggested to predict response to treatment with tricyclic antidepressive drugs. In order to examine whether BPV predict response to selective mono-aminergic therapy, 24 in-patients with major depression were treated in a single-masked, randomised study using the most selective noradrenergic or serotonergic reuptake inhibitors available for antidepressant treatment, i.e. reboxetine and citalopram. A significant correlation between BPV and treatment response to reboxetine was found, but not between BPV and response to citalopram. As BPV are influenced by noradrenergic activity, it can be hypothesized that depressed patients with comparatively high BPV have a relatively high noradrenergic function. This might explain why in our study depressed patients with the highest BPV responded strongest to selective noradrenergic treatment with reboxetine. As measurement of BPV is simple, further studies are suggested to examine the possible clinical value of the link between prolactin, noradrenergic function in major depression and treatment response.
authors.affiliation: Affective Disorders Research Unit, Department of Psychiatry, University of Münster, Münster, Germany. olaff.moeller4345@t-online.de
authors.forename: Olaf
authors.initials: O
authors.lastname: Moeller
authors.forename: Guenter
authors.initials: G
authors.lastname: Hetzel
authors.forename: Nikolaus
authors.initials: N
authors.lastname: Michael
authors.forename: Matthias
authors.initials: M
authors.lastname: Rothermundt
authors.forename: Volker
authors.initials: V
authors.lastname: Arolt
authors.forename: Andreas
authors.initials: A
authors.lastname: Erfurth
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use*; D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use*; D015283:Citalopram / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000097:blood* / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use*; D011388:Prolactin / Q000097:blood*; D011569:Psychiatric Status Rating Scales; D000077593:Reboxetine; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*
chemical_list: D018759:Adrenergic Uptake Inhibitors; D000928:Antidepressive Agents; D015283:Citalopram; D009025:Morpholines; D011388:Prolactin; D000077593:Reboxetine; D017367:Selective Serotonin Reuptake Inhibitors